List of reported rifampin drug-drug interactions with either intravenously or orally administered CYP3A4 victim drugs
Details of the references are listed in the supplemental data.
| Intravenous Induction DDI Dataset | Oral Induction DDI Dataset | ||||||
|---|---|---|---|---|---|---|---|
| Victim Drug | EHa | AUC Fold Change | Reference | Victim Drug | fmCYP3A4b | AUC Fold Change | Reference |
| Alfentanil | 0.32 | 2.7 | Kharasch et al., 2004 | Alfentanil | 0.87 | 21.9 | Kharasch et al., 2004 |
| Alfentanil | 0.32 | 2.8 | Kharasch et al., 1997 | Alprazolam | 0.80 | 8.5 | Schmider et al., 1999 |
| Alfentanil | 0.32 | 2.3 | Phimmasone et al., 2001 | Atorvastatin | 0.77 | 5.1 | Backman et al., 2005 |
| Cyclosporine | 0.19 | 1.4 | Hebert et al., 1992 | Cyclosporine | 0.71 | 3.7 | Hebert et al., 1992 |
| Midazolam | 0.54 | 2.1 | Phimmasone et al., 2001 | Midazolam | 0.94 | 7.2 | Adams et al., 2005 |
| Midazolam | 0.54 | 1.5 | Link et al., 2008 | Midazolam | 0.94 | 8.0 | Chung et al., 2006 |
| Midazolam | 0.54 | 1.9 | Kharasch et al., 2004 | Midazolam | 0.94 | 19.1 | Eap et al., 2004 |
| Midazolam | 0.54 | 2.6 | Kharasch et al., 1997 | Midazolam | 0.94 | 14.5 | Gorski et al., 2003 |
| Midazolam | 0.54 | 2.2 | Gorski et al., 2003 | Midazolam | 0.94 | 17.7 | Gurley et al., 2006 |
| Midazolam | 0.54 | 1.9 | Yu et al., 2004 | Midazolam | 0.94 | 19.0 | Kharasch et al., 2004 |
| Midazolam | 0.54 | 2.3 | Yu et al., 2004 | Midazolam | 0.94 | 14.6 | Floyd et al., 2003 |
| Midazolam | 0.54 | 2.3 | Yu et al., 2004 | Nifedipine | 0.71 | 12.2 | Holtbecker et al., 1996 |
| Midazolam | 0.54 | 1.8 | Floyd et al., 2003 | Quinidine | 0.76 | 6.0 | Twum-Barima et al., 1981 |
| Midazolam | 0.54 | 2.3 | Eeckhoudt et al., 2001 | Quinidine | 0.76 | 8.8 | Damkier et al., 1999 |
| Nifedipine | 0.54 | 1.4 | Holtbecker et al., 1996 | Repaglinide | 0.49 | 4.9 | Bidstrup et al., 2004 |
| Quinidine | 0.21 | 3.7 | Twum-Barima et al., 1981 | Repaglinide | 0.49 | 2.4 | Niemi et al., 2000 |
| Tacrolimus | 0.03 | 1.5 | Hebert et al., 1999 | Repaglinide | 0.49 | 1.5 | Hatorp et al., 2003 |
| Verapamil | 0.64 | 1.2 | Barbarash et al., 1988 | Tacrolimus | 0.99 | 3.1 | Hebert et al., 1999 |
| Triazolam | 0.92 | 20.0 | Villikka et al., 1997 | ||||
| Verapamil | 0.30 | 15.4 | Barbarash et al., 1988 | ||||
| Zolpidem | 0.60 | 3.6 | Villikka et al., 1997 | ||||
a Hepatic extraction ratio calculated from reported intravenous clearance data (Gertz et al., 2010).
b Fraction metabolized by CYP3A4. Values were collected from the literature (Houston and Galetin, 2008; Shou et al., 2008) (alfentanil, verapamil).